Bintrafusp alfa with cCRT followed by bintrafusp alfa versus placebo with cCRT followed by durvalumab in patients with unresectable stage III NSCLC: A phase 2 randomized study

By sjmartinez • October 6, 2023

Vokes EE, Mornex F, Sezer A, Cheng Y, Fang J, Baz DV, Cil T, Adjei AA, Ahn MJ, Barlesi F, Felip E, Garon EB, Audhuy F, Ito R, Sato M, Eggleton SP, Martin CM, Reck M, Robinson CG, Paz-Ares L. Bintrafusp alfa with cCRT followed by bintrafusp alfa versus placebo with cCRT followed by durvalumab in patients with unresectable stage III NSCLC: A phase 2 randomized study. J Thorac Oncol. 2023 Oct 3:S1556-0864(23)02262-1. doi: 10.1016/j.jtho.2023.09.1452. Epub ahead of print. PMID: 37797733.

Tags: bifunctional, bintrafusp alfa, concurrent chemoradiotherapy, Hematology/Oncology, non-small-cell lung cancer, Publications, TGF-β

Related Posts

CPX-351 plus gemtuzumab ozogamicin for relapsed/refractory acute myelogenous leukemia: a University of California Hematologic Malignancies Consortium trial

Oliai C, Park S, Damon LE, Jonas BA, Jeyakumar D, Wieduwilt MJ, Logan AC, Callas B, Hannigan CA, Gaut DL, Schiller GJ. CPX-351 plus gemtuzumab[...]

Efficacy and Safety of Atezolizumab plus Bevacizumab versus Sorafenib in Hepatocellular Carcinoma with Main Trunk and/or Contralateral Portal Vein Invasion in IMbrave150

Finn RS, Galle PR, Ducreux M, Cheng AL, Reilly N, Nicholas A, Hernandez S, Ma N, Merle P, Salem R, Li D, Breder V. Efficacy[...]

Overcoming Challenges in Small-Molecule Drug Bioavailability: A Review of Key Factors and Approaches

Wu K, Kwon SH, Zhou X, Fuller C, Wang X, Vadgama J, Wu Y. Overcoming Challenges in Small-Molecule Drug Bioavailability: A Review of Key Factors[...]